Salivary proteomics in monitoring the therapeutic response of canine oral melanoma.

Saliva biomarkers are suitable for monitoring the therapeutic response of canine oral melanoma (COM), because saliva directly contacts the tumor, and saliva collection is non-invasive, convenient and cost effective. The present study aimed to investigate novel biomarkers from the salivary proteome o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sekkarin Ploypetch, Sittiruk Roytrakul, Janthima Jaresitthikunchai, Narumon Phaonakrop, Patharakrit Teewasutrakul, Anudep Rungsipipat, Gunnaporn Suriyaphol
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8a622ebe076a4ae3809ac26099953560
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8a622ebe076a4ae3809ac26099953560
record_format	dspace
spelling	oai:doaj.org-article:8a622ebe076a4ae3809ac260999535602021-12-02T20:17:45ZSalivary proteomics in monitoring the therapeutic response of canine oral melanoma.1932-620310.1371/journal.pone.0256167https://doaj.org/article/8a622ebe076a4ae3809ac260999535602021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0256167https://doaj.org/toc/1932-6203Saliva biomarkers are suitable for monitoring the therapeutic response of canine oral melanoma (COM), because saliva directly contacts the tumor, and saliva collection is non-invasive, convenient and cost effective. The present study aimed to investigate novel biomarkers from the salivary proteome of COM treated with surgery and a chemotherapy drug, carboplatin, 1-6 times, using a liquid chromatography-tandem mass spectrometry approach. The expression of a potential salivary biomarker, ubiquitin D (UBD), was observed and verified by western blot analysis. A significantly increased ratio of free UBD (fUBD) to conjugated UBD (cUBD) was shown in the pre-surgery stage (PreS) in OM dogs with short-term survival (STS) (less than 12 months after surgery) compared with that with long-term survival (more than 12 months after surgery). In dogs with STS, the ratio was also shown to be augmented in PreS compared with that after surgery, followed by treatment with carboplatin twice, 4 and 5 times [After treatment (AT)2, AT4 and AT5]. In addition, the expression of fUBD was enhanced in PreS compared with that of AT2 in the STS group. In conclusion, this study revealed that a ratio of fUBD to cUBD in PreS was plausibly shown to be a potential prognostic biomarker for survival in dogs with OM.Sekkarin PloypetchSittiruk RoytrakulJanthima JaresitthikunchaiNarumon PhaonakropPatharakrit TeewasutrakulAnudep RungsipipatGunnaporn SuriyapholPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 8, p e0256167 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sekkarin Ploypetch Sittiruk Roytrakul Janthima Jaresitthikunchai Narumon Phaonakrop Patharakrit Teewasutrakul Anudep Rungsipipat Gunnaporn Suriyaphol Salivary proteomics in monitoring the therapeutic response of canine oral melanoma.
description	Saliva biomarkers are suitable for monitoring the therapeutic response of canine oral melanoma (COM), because saliva directly contacts the tumor, and saliva collection is non-invasive, convenient and cost effective. The present study aimed to investigate novel biomarkers from the salivary proteome of COM treated with surgery and a chemotherapy drug, carboplatin, 1-6 times, using a liquid chromatography-tandem mass spectrometry approach. The expression of a potential salivary biomarker, ubiquitin D (UBD), was observed and verified by western blot analysis. A significantly increased ratio of free UBD (fUBD) to conjugated UBD (cUBD) was shown in the pre-surgery stage (PreS) in OM dogs with short-term survival (STS) (less than 12 months after surgery) compared with that with long-term survival (more than 12 months after surgery). In dogs with STS, the ratio was also shown to be augmented in PreS compared with that after surgery, followed by treatment with carboplatin twice, 4 and 5 times [After treatment (AT)2, AT4 and AT5]. In addition, the expression of fUBD was enhanced in PreS compared with that of AT2 in the STS group. In conclusion, this study revealed that a ratio of fUBD to cUBD in PreS was plausibly shown to be a potential prognostic biomarker for survival in dogs with OM.
format	article
author	Sekkarin Ploypetch Sittiruk Roytrakul Janthima Jaresitthikunchai Narumon Phaonakrop Patharakrit Teewasutrakul Anudep Rungsipipat Gunnaporn Suriyaphol
author_facet	Sekkarin Ploypetch Sittiruk Roytrakul Janthima Jaresitthikunchai Narumon Phaonakrop Patharakrit Teewasutrakul Anudep Rungsipipat Gunnaporn Suriyaphol
author_sort	Sekkarin Ploypetch
title	Salivary proteomics in monitoring the therapeutic response of canine oral melanoma.
title_short	Salivary proteomics in monitoring the therapeutic response of canine oral melanoma.
title_full	Salivary proteomics in monitoring the therapeutic response of canine oral melanoma.
title_fullStr	Salivary proteomics in monitoring the therapeutic response of canine oral melanoma.
title_full_unstemmed	Salivary proteomics in monitoring the therapeutic response of canine oral melanoma.
title_sort	salivary proteomics in monitoring the therapeutic response of canine oral melanoma.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/8a622ebe076a4ae3809ac26099953560
work_keys_str_mv	AT sekkarinploypetch salivaryproteomicsinmonitoringthetherapeuticresponseofcanineoralmelanoma AT sittirukroytrakul salivaryproteomicsinmonitoringthetherapeuticresponseofcanineoralmelanoma AT janthimajaresitthikunchai salivaryproteomicsinmonitoringthetherapeuticresponseofcanineoralmelanoma AT narumonphaonakrop salivaryproteomicsinmonitoringthetherapeuticresponseofcanineoralmelanoma AT patharakritteewasutrakul salivaryproteomicsinmonitoringthetherapeuticresponseofcanineoralmelanoma AT anudeprungsipipat salivaryproteomicsinmonitoringthetherapeuticresponseofcanineoralmelanoma AT gunnapornsuriyaphol salivaryproteomicsinmonitoringthetherapeuticresponseofcanineoralmelanoma
_version_	1718374355557154816

Salivary proteomics in monitoring the therapeutic response of canine oral melanoma.

Ejemplares similares